Stock

CVS Health to pull decongestants with phenylephrine off shelves

U.S. pharmacy chain CVS Health said on Thursday it is pulling some of the most common decongestants with phenylephrine as the only active ingredient from its shelves and will no longer sell them.

The move comes after a panel of advisers to U.S. health regulators raised doubts over the efficacy of the ingredient.

Last month, the panel refused to back the effectiveness of oral over-the-counter (OTC) medicines made with phenylephrine, adding that no more trials were required to prove otherwise.

CVS said “other oral cough and cold products will continue to be offered to meet consumer needs.”

Phenylephrine was substituted for pseudoephedrine in many non-prescription cold and allergy medicines after the latter was restricted amid reports of abuse.

Phenylephrine is a major component used in some of popular products like Benadryl, Sudafed, GSK’s Advil and Kenvue’s Tylenol.

This post appeared first on NBC NEWS

You May Also Like

Stock

Union members at Ford, Stellantis and General Motors have ratified a new 4½-year contract, locking in at 11% pay increases secured after a six-week...

Investing

ASX-listed Antilles Gold (ASX:AAU, OTCQB:ANTMF) is an Australian mining company focused on gold and copper projects in Cuba through joint ventures with the Cuban...

Latest News

A man accused of murdering his girlfriend in Boston before fleeing to Kenya has been re-arrested following his escape from a police station in...

Latest News

Slovakian police have charged a man in connection with the attempted assassination of Prime Minister Robert Fico, the country’s interior minister said Thursday. Fico...

Disclaimer: Nationalfinancialnews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 nationalfinancialnews.com